GPX1 and fatty liver disease: While this suggests increased ROS does not necessarily lead to hepatic insulin resistance and fatty liver disease, global GPx1 deletion and the general failure of these mice to gain fat mass makes it difficult to isolate direct effects of GPx1 loss on liver metabolism.